CO6220977A2 - Sintesis total de salinosporamida a y analogos de las misma - Google Patents

Sintesis total de salinosporamida a y analogos de las misma

Info

Publication number
CO6220977A2
CO6220977A2 CO08115223A CO08115223A CO6220977A2 CO 6220977 A2 CO6220977 A2 CO 6220977A2 CO 08115223 A CO08115223 A CO 08115223A CO 08115223 A CO08115223 A CO 08115223A CO 6220977 A2 CO6220977 A2 CO 6220977A2
Authority
CO
Colombia
Prior art keywords
compound
formula
salinosporamida
analogs
same
Prior art date
Application number
CO08115223A
Other languages
English (en)
Inventor
Taotao Ling
Venkata Rami Reddy Macherla
Barbara Christine Potts
Rama Rao Manan
Katherine Mcarthur
Original Assignee
Nereus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nereus Pharmaceuticals Inc filed Critical Nereus Pharmaceuticals Inc
Publication of CO6220977A2 publication Critical patent/CO6220977A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

1.- Un método para la síntesis química, que comprende las etapas de: (a) hacer reaccionar un compuesto de la fórmula (I): con un compuesto de la fórmula (II):para formar un compuesto de la fórmula (III)(b) desproteger el compuesto de la fórmula (III) para formar un compuesto de la fórmula (IV)(c) llevar a cabo una reacción de aldol intramolecular en el compuesto de la fórmula (IV) para formar un compuesto de la fórmula (V):(d) romper el enlace doble de carbono-carbono del compuesto de la fórmula (V) y ciclar el enlace doble roto con el grupo hidroxi terciario para formar un compuesto de la fórmula (VI):(e) proteger el hemiacetal del compuesto de la fórmula (VI) para formar un compuesto de la fórmula (VII):(f) reducir el grupo COOR2 ...
CO08115223A 2006-04-06 2008-10-28 Sintesis total de salinosporamida a y analogos de las misma CO6220977A2 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79016806P 2006-04-06 2006-04-06
US81696806P 2006-06-27 2006-06-27
US83615506P 2006-08-07 2006-08-07
US84413206P 2006-09-12 2006-09-12
US88537907P 2007-01-17 2007-01-17

Publications (1)

Publication Number Publication Date
CO6220977A2 true CO6220977A2 (es) 2010-11-19

Family

ID=38529634

Family Applications (1)

Application Number Title Priority Date Filing Date
CO08115223A CO6220977A2 (es) 2006-04-06 2008-10-28 Sintesis total de salinosporamida a y analogos de las misma

Country Status (15)

Country Link
US (2) US7842814B2 (es)
EP (2) EP2013167B1 (es)
JP (1) JP2009532484A (es)
KR (1) KR20080109071A (es)
CN (2) CN102718776A (es)
AU (1) AU2007235323C1 (es)
BR (1) BRPI0709474A2 (es)
CA (1) CA2648317A1 (es)
CO (1) CO6220977A2 (es)
HK (1) HK1128279A1 (es)
IL (1) IL194507A0 (es)
MX (1) MX2008012847A (es)
NZ (2) NZ596653A (es)
WO (1) WO2007117591A2 (es)
ZA (1) ZA200809305B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176232B2 (en) 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
CN101791306A (zh) * 2003-06-20 2010-08-04 加利福尼亚大学董事会 盐孢菌酰胺及其使用方法
CA2532066C (en) 2003-06-20 2015-07-28 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101155582B (zh) 2004-12-03 2013-04-24 达纳-法伯癌症研究公司 治疗肿瘤性疾病的组合物和方法
BRPI0709474A2 (pt) 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0909661A2 (pt) 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
CA2723465A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
JP7171550B2 (ja) 2016-06-01 2022-11-15 セルジュヌ アンテルナシオナル ドゥジエム ソシエテ ア レスポンサビリテ リミティー 中枢神経系（ｃｎｓ）がんの処置のためのマリゾミブの使用
WO2018033631A1 (en) 2016-08-19 2018-02-22 Celgene International Ii Sàrl Morphic forms of marizomib and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
CA2301054A1 (en) 1997-08-15 1999-02-25 Francois Soucy Synthesis of clasto-lactacystin .beta.-lactone and analogs thereof
EP1017398A1 (en) 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-kb via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
JP3794469B2 (ja) 1998-03-26 2006-07-05 塩野義製薬株式会社 抗ウイルス作用を有するインドール誘導体
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU4322802A (en) * 2000-11-16 2002-06-24 Univ California Marine actinomycete taxon for drug and fermentation product dicovery
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
US7179834B2 (en) 2002-06-24 2007-02-20 The Regents Of The University Of California Salinosporamides and methods for use thereof
EP1597262B1 (en) 2003-02-14 2009-11-11 InterMed Discovery GmbH Substituted heterocycles
CA2532066C (en) 2003-06-20 2015-07-28 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7371875B2 (en) 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
WO2005099687A2 (en) * 2004-04-09 2005-10-27 President And Fellows Of Harvard College Analogs of salinosporamide a
US7183417B2 (en) 2004-04-09 2007-02-27 President And Fellows Of Harvard College Simple stereocontrolled synthesis of salinosporamide A
US20060264495A1 (en) 2004-04-30 2006-11-23 Michael Palladino Methods of using [3.2.0] heterocyclic compounds and analogs thereof
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2006028525A2 (en) 2004-04-30 2006-03-16 Nereus Pharmaceuticals, Inc. [3.2.0] heterocyclic compounds and methods of using the same
WO2006005551A1 (en) 2004-07-12 2006-01-19 Bayer Cropscience Ag Substituted 2-pyrrolidone derivatives as fungicides and insecticides
CN101155582B (zh) 2004-12-03 2013-04-24 达纳-法伯癌症研究公司 治疗肿瘤性疾病的组合物和方法
CA2590334A1 (en) 2004-12-03 2006-06-08 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
WO2006118973A2 (en) 2005-04-29 2006-11-09 Nereus Pharmaceuticals, Inc. Methods of using heterobyclic compounds for treatment of rectal cancer
US20060287520A1 (en) * 2005-05-16 2006-12-21 Danishefsky Samuel J Synthesis of salinosporamide A and analogues thereof
EP1931679A4 (en) 2005-08-10 2009-07-29 Harvard College ANALOGUE OF SALINOSPORAMIDE A
US7691896B2 (en) * 2005-08-10 2010-04-06 President And Fellows Of Harvard College Analogs of salinosporamide A
US7465720B2 (en) 2005-09-12 2008-12-16 President And Fellows Of Harvard College Proteasome inhibiting β-lactam compounds
US7759327B2 (en) * 2006-01-06 2010-07-20 The Trustees Of Columbia University In The City Of New York Compositions containing zinc salts for coating medical articles
BRPI0709474A2 (pt) * 2006-04-06 2011-07-12 Nerus Pharmaceuticals Inc sìntese total de salinosporamida a e seus análogos
BRPI0909661A2 (pt) * 2008-03-07 2015-08-11 Nereus Pharmaceuticals Inc Composto e métodos de síntese química e de formação ou preparação de compostos
CA2723465A1 (en) * 2008-05-12 2009-11-19 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
US11826005B2 (en) 2022-03-29 2023-11-28 Midea Group Co., Ltd. Exhibiting a dishwasher rack to the user

Also Published As

Publication number Publication date
WO2007117591A3 (en) 2008-05-08
AU2007235323B2 (en) 2011-09-08
US8067616B2 (en) 2011-11-29
IL194507A0 (en) 2009-08-03
AU2007235323A1 (en) 2007-10-18
US20070249693A1 (en) 2007-10-25
BRPI0709474A2 (pt) 2011-07-12
KR20080109071A (ko) 2008-12-16
EP2631237A2 (en) 2013-08-28
US7842814B2 (en) 2010-11-30
EP2013167A2 (en) 2009-01-14
EP2013167B1 (en) 2012-09-05
NZ596653A (en) 2012-10-26
HK1128279A1 (en) 2009-10-23
NZ572026A (en) 2011-12-22
ZA200809305B (en) 2011-10-26
US20110105762A1 (en) 2011-05-05
CN101460457B (zh) 2012-07-18
MX2008012847A (es) 2008-10-13
JP2009532484A (ja) 2009-09-10
WO2007117591A2 (en) 2007-10-18
CN102718776A (zh) 2012-10-10
CA2648317A1 (en) 2007-10-18
AU2007235323C1 (en) 2012-05-10
WO2007117591A9 (en) 2008-10-02
CN101460457A (zh) 2009-06-17

Similar Documents

Publication Publication Date Title
CO6220977A2 (es) Sintesis total de salinosporamida a y analogos de las misma
AR066773A1 (es) Proceso para preparar alcoxidos de metales alcalinos
EA200800886A1 (ru) Способ получения 1-н-имидазо[4,5-с]пиридинов и их аналогов
DK1838652T3 (da) Nye duftstofforbindelser samt syntesefremgangsmåde og anvendelser heraf
CY1111045T1 (el) Μεθοδος παραγωγης ενος παραγωγου βενζιμιδαζολιου
UA107175C2 (uk) Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
AR072143A1 (es) Procedimiento para la preparacion de un producto intermedio para la sintesis de etexilato de dabigatran
NO20084547L (no) Fremgangsmate for fremstilling av HIV-proteaseinhibitorer
EA201101015A1 (ru) Способ получения бивалирудина
CL2012000560A1 (es) Procedimiento de preparacion del compuesto intermediario acido 3-oxo-tetrahidrotiofeno-2-carboxilico, utiles en la preparacion de dihidrotienopirimidinas (divisional de la solicitud 3095-08).
CR10557A (es) Bencilaminas, un proceso para la produccion y su uso como agentes antiinflamatorios
UA101835C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
AR080656A1 (es) Sintesis de magnolol y sus compuestos analogos, y composicion farmaceutica
MX2010001478A (es) Derivados de ciclohexeno y su uso como odorantes.
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
AR074545A1 (es) Proceso de preparacion de dihidroetorfina
CL2007003844A1 (es) Procedimiento para mejorar la utilizacion del potencial de produccion de una planta transgenica mediante el tratamiento con un compuesto derivado de 3-aril-pirrolidin-2,4-diona.
UY33447A (es) Procedimiento de sintesis de la ferroquina por animacion reductora convergente
AR061490A1 (es) Productos de condensacion de dialdehido con contenido en grupos acido
CR20110111A (es) Composicion farmaceutica solida
AR060216A1 (es) Procesos para preparar ezetimibe y compuestos intermediarios utiles para su preparacion
CR20110208A (es) Proceso para la preparación de benzonorbornenos
AR048099A1 (es) FORMA CRISTALINA DE ÁCIDO 8-CIANO-1CICLOPROPIL-7-(1S,6S-2,8-DIAZABICICLO)(4.3.0)NONAN--IL)-6FLUOR-1,4-DIHIDRO-4-OXO-3-QUINOLINCARBOXíLICO
ES2548480T3 (es) Procedimiento de producción de levosandal

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed